SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from HC Wainwright

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 380.00% from the stock’s current price.

Separately, Chardan Capital restated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $11.40.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ SABS opened at $1.25 on Tuesday. The firm’s 50-day moving average price is $1.89 and its 200-day moving average price is $2.81. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a 1-year low of $1.11 and a 1-year high of $5.01.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Friday, March 28th. The company reported ($1.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.07). The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.12 million. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. On average, equities research analysts expect that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

A number of large investors have recently added to or reduced their stakes in the stock. HB Wealth Management LLC increased its position in SAB Biotherapeutics by 118.6% in the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after buying an additional 128,800 shares during the last quarter. Kovitz Investment Group Partners LLC bought a new position in shares of SAB Biotherapeutics during the 3rd quarter worth $52,000. Northern Trust Corp purchased a new stake in SAB Biotherapeutics in the 4th quarter worth about $43,000. Geode Capital Management LLC raised its stake in SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after acquiring an additional 12,692 shares during the period. Finally, Diadema Partners LP purchased a new stake in SAB Biotherapeutics during the fourth quarter valued at about $114,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.